Born in Conflenti (CZ) in 1951, Lorenzo Tallarigo attained a Medical degree from the University of Pisa and a PMD from Harvard Business School.
He went on to gain experience in Eli Lilly, where he held various roles of increasing responsibility: clinical research, marketing, general management, eventually becoming President of International Operations.
He was the Chairman of Intercept Pharmaceuticals, which he led to the company’s IPO.
He was also Chief Executive Officer of Genextra, where he remains a board member.
He was appointed non-executive Chairman of Oxford Biomedica in 2016.
He has been on the Board of Directors of Angelini Holding S.p.A. since 1 January 2019.